Interactions between natural health products and antiretroviral drags: Pharmacokinetic and pharmacodynamic effects

Clinical Infectious Diseases

Volumn 43, Issue 8, 2006, Pages 1052-1059

  Lee, Lawrence S ^a   Andrade, Adriana S A ^b   Flexner, Charles ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPRAZOLAM; ANTIRETROVIRUS AGENT; ASCORBIC ACID; CARRIER PROTEIN; CYTOCHROME P450; CYTOCHROME P450 3A4; ECHINACEA EXTRACT; ENZYME; FISH OIL; GARLIC EXTRACT; GARLIPURE; GLYCOPROTEIN P; GOLDENSEAL ROOT HERBAL SINGLE; HERBACEOUS AGENT; HYDRASTIS EXTRACT; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; LAMIVUDINE; LOPINAVIR; MIDAZOLAM; NATURAL PRODUCT; NEVIRAPINE; ODOURLESS GARLIC LIFE BRAND; ORGANIC COMPOUND; PLANT EXTRACT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SILYBUM MARIANUM EXTRACT; STAVUDINE; THISILYN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSPORT; DRUG TREATMENT FAILURE; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRASTIS; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; HERB-DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 33750316890     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/507894     Document Type: Review

References (80)

1. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005; 11:42-9.
2. Risa KJ, Nepon L, Justis JC, et al. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. Int J STD AIDS 2002; 13:706-13.
3. Gore-Felton C, Vosvick M, Power R, et al. Alternative therapies: a common practice among men and women living with HIV. J Assoc Nurses AIDS Care 2003; 14:17-27.
4. Standish LJ, Greene KB, Bain S, et al. Alternative medicine use in HIV-positive men and women: demographics, utilization patterns and health status. AIDS Care 2001; 13:197-208.
5. Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J. Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDS 2001; 15:159-67.
6. Rivera JO, Gonzalez-Stuart A, Ortiz M, Rodriguez JC, Anaya JP, Meza A. Herbal product use in non-HIV and HIV-positive Hispanic patients. J Natl Med Assoc 2005; 97:1686-91.
7. Wynia MK, Eisenberg DM, Wilson IB. Physician-patient communication about complementary and alternative medical therapies: a survey of physicians caring for patients with human immunodeficiency virus infection. J Altern Complement Med 1999; 5:447-56.
8. Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001; 45:30-7.
9. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
10. Gonzalez de Requena D, Gallego O, de Mendoza C, Corral A, Jimenez-Nacher I, Soriano V. Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. AIDS Res Hum Retroviruses 2003; 19:457-9.
11. Duong M, Buisson M, Peytavin G, et al. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother 2005; 39:603-9.
12. Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003; 47:594-600.
13. Solas C, Basso S, Poizot-Martin I, et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002; 29:374-7.
14. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005;41:1648-53.
15. Chang TK, Waxman DJ. Pregnane X receptor-mediated transcription. Methods Enzymol 2005; 400:588-98.
16. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30:795-804.
17. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97:7500-2.
18. Sato PH, Zannoni VG. Stimulation of drug metabolism by ascorbic acid in weanling guinea-pigs. Biochem Pharmacol 1974; 23:3121-8.
19. Brigelius-Flohe R. Induction of drug metabolizing enzymes by vitamin E. J Plant Physiol 2005; 162:797-802.
20. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35:35-98.
21. Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM. Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice. Antimicrob Agents Chemother 2002; 46:1589-90.
22. Penzak SR, Acosta EP, Turner M, et al. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol 2002; 42:1165-70.
23. Shelton MJ, Wynn HE, Hewitt RG, DiFrancesco R. Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J Clin Pharmacol 2001; 41:435-42.
24. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45:355-9.
25. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004; 32:587-94.
26. Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4:176-84.
27. Wu CC, Sheen LY, Chen HW, Kuo WW, Tsai SJ, Lii CK. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 2002; 50: 378-83.
28. Mills E, Cooper C, Seely D, Kanfer I. African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J 2005; 4:19.
29. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999;65:PL209-14.
30. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004; 79:727-47.
31. Katragadda S, Budda B, Anand BS, Mitra AK. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin Drug Deliv 2005; 2:683-705.
32. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28:655-60.
33. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004; 54: 982-90.
34. Speck RR, Yu XF, Hildreth J, Flexner C. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002; 186:332-40.
35. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005; 28:249-68.
36. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304:1258-67.
37. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36:57-104.
38. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 1992; 89:2399-403.
39. Fukao T, Hosono T, Misawa S, Seki T, Ariga T. The effects of allyl sulfides on the induction of phase II detoxification enzymes and liver injury by carbon tetrachloride. Food Chem Toxicol 2004; 42:743-9.
40. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005; 12:559-67.
41. DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23:866-70.
42. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002; 22:551-6.
43. Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005; 61:1-7.
44. Gurley B, Hubbard MA, Williams DK, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006; 46:201-13.
45. Gurley BJ, Barone GW, Williams DK, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2006; 34:69-74.
46. Linde K, Mulrow CD, Berner M, Egger M. St. John's wort for depression. Cochrane Database Syst Rev 2005; CD000448.
47. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 2004; 27:773-97.
48. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355:547-8.
49. de Maat MM, Hoetelmans RM, Math t RA, et al. Drug interaction between St John's wort and nevirapine. AIDS 2001; 15:420-1.
50. Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62:29-36.
51. Zanoli P. Role of hyperforin in the pharmacological activities of St. John's Wort. CNS Drug Rev 2004; 10:203-18.
52. Tattelman E. Health effects of garlic. Am Fam Physician 2005; 72:103-6.
53. Piscitelli SC, Burstein AH, Weiden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34:234-8.
54. Dupuis ML, Flego M, Molinari A, Cianfriglia M. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. HIV Med 2003; 4:338-45.
55. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003; 55:199-202.
56. Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22:525-39.
57. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74:170-7.
58. Borek C. Garlic supplements and saquinavir. Clin Infect Dis 2002; 35: 343.
59. Lawson LD, Wang ZJ. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. J Agric Food Chem 2001; 49:2592-9.
60. Laroche M, Choudhri S, Gallicano K, Foster B. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can J Infect Dis 1998; 9 (Suppl A):471P.
61. Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy 2005; 25:165-70.
62. Rehman J, Dillow JM, Carter SM, Chou J, Le B, Maisel AS. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett 1999; 68:391-5.
63. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7:273-82.
64. Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 2003; 43:1283-8.
65. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77: 415-26.
66. Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75:89-100.
67. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76:428-40.
68. Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 2003; 31: 519-22.
69. Garrard J, Harms S, Eberly LE, Matiak A. Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 2003; 163:2290-5.
70. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001; 73:1101-6.
71. Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Arch Intern Med 2003; 163:699-704.
72. Wu JA, Attele AS, Zhang L, Yuan CS. Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 2001; 29: 69-81.
73. Chen JJ, Luo SD, Wang YF, Zheng YT. The collection of active compounds of anti-HIV/AIDS. Kunming: Yunnan Science and Technology Publishing House, 2002.
74. Sangkitporn S, Shide L, Klinbuayaem V, et al. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Southeast Asian J Trop Med Public Health 2005; 36:704-8.
75. Liu JP, Manheimer E, Yang M. Herbal medicines for treating HIV infection and AIDS. Cochrane Database Syst Rev 2005; CD003937.
76. Tan BK, Vanitha J. Immunomodulatory and antimicrobial effects of some traditional chinese medicinal herbs: a review. Curr Med Chem 2004; 11:1423-30.
77. Ramgolam V, Ang SG, Lai YH, Loh CS, Yap HK. Traditional Chinese medicines as immunosuppressive agents. Ann Acad Med Singapore 2000; 29:11-6.
78. Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis 2003; 37:959-72.
79. Gerber J, Kitch D, Aberg J, et al. The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: results of A5186 [abstract 146]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2006:100.
80. Holodniy M, Koch J, Mistal M, et al. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol 1999; 94:3267-73.